Delivery Order SPE2DB20D7061-SPE2DB24FSPQ8

Award Date 8/28/24
Potential Completion Date 8/29/24
Potential Value $3.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin PH 1% Gel, a prescription medication, with a ceiling value of $1,029.48 and a period of performance through May 19, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a...
The Defense Logistics Agency (DLA) has awarded a delivery order contract to Amerisourcebergen Drug Corp in the amount of $2,036.40 for the supply of CLINDAMYCIN PH 1% SOLUTION 60ML. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. The contract does not have a set-aside...
This is a federal delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of Clindamycin Phosphate 1% Lotion, 60 ml, with a ceiling value of $1,191.60 and a period of performance ending on July 14, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating it was competitively awarded. Amerisourcebergen Drug Corp holds a substantial...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,888.43 firm fixed-price contract is for the supply of Clindamycin Phosphate 1% gel, a topical antibiotic medication. This order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA's Troop Support Medical division, valued at $999,999,999 and running through November 2026. The IDC serves as a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin PH 1% Solution 60ML, a pharmaceutical product, with a ceiling value of $3,819.08 and a completion date of July 14, 2025. The contract is a firm fixed price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The award has a ceiling value of $1,121.36 and is for the delivery of clindamycin phosphate 1% lotion, a topical antibiotic medication. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4562692183 CLINDAMYCIN 900 MG/50 ML-D5W 50ML, with a ceiling value of $2,616.04 and a period of performance through November 3, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of a pharmaceutical product, Clindamycin PH 1% Solution 30ML. The contract has a ceiling value of $3,091.30 and an ultimate completion date of March 18, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of...
This federal contract award, valued at $1,154.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin 900 mg/50 ml-D5W 50 ml, a pharmaceutical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The $14,227.04 firm-fixed-price contract is for the supply of 4,558,931,304 units of Clindamycin 60GM 1S, a pharmaceutical product. This order is under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which provides a wide range of medical commodities to...
  • SPE2DB20D7061
    Indefinite Delivery Contract
  • SPE2DB20D7061-SPE2DB24FSPQ8
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor, for the supply of Clindamycin 2% vaginal cream, a prescription medication. The contract has a firm fixed price and a ceiling value of $3,260.78. The delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of medical commodities, including prescription drugs, to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is expected to be completed by August 29, 2024.

Generated 11/27/24, 9:23 AM